[go: up one dir, main page]

HK1158229A1 - C-met antibodies c-met - Google Patents

C-met antibodies c-met

Info

Publication number
HK1158229A1
HK1158229A1 HK11112740.5A HK11112740A HK1158229A1 HK 1158229 A1 HK1158229 A1 HK 1158229A1 HK 11112740 A HK11112740 A HK 11112740A HK 1158229 A1 HK1158229 A1 HK 1158229A1
Authority
HK
Hong Kong
Prior art keywords
met
antibodies
met antibodies
Prior art date
Application number
HK11112740.5A
Other languages
English (en)
Chinese (zh)
Inventor
Julian Davies
Ling Liu
Jirong Lu
Peter Edward Vaillancourt
Mark Andrew Wortinger
Wei Zeng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1158229A1 publication Critical patent/HK1158229A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK11112740.5A 2008-11-21 2011-11-24 C-met antibodies c-met HK1158229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11682508P 2008-11-21 2008-11-21
US21990309P 2009-06-24 2009-06-24
PCT/US2009/064881 WO2010059654A1 (en) 2008-11-21 2009-11-18 c-MET ANTIBODIES

Publications (1)

Publication Number Publication Date
HK1158229A1 true HK1158229A1 (en) 2012-07-13

Family

ID=41435259

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112740.5A HK1158229A1 (en) 2008-11-21 2011-11-24 C-met antibodies c-met

Country Status (28)

Country Link
US (2) US8217148B2 (he)
EP (2) EP2963058B1 (he)
JP (1) JP5688027B2 (he)
KR (1) KR101334450B1 (he)
CN (1) CN102216333B (he)
AR (1) AR074360A1 (he)
AU (1) AU2009316742B2 (he)
BR (1) BRPI0922800A2 (he)
CA (1) CA2743508C (he)
CY (1) CY1116886T1 (he)
DK (1) DK2358755T3 (he)
EA (1) EA020398B1 (he)
ES (2) ES2663825T3 (he)
HK (1) HK1158229A1 (he)
HR (1) HRP20151019T1 (he)
HU (1) HUE026058T2 (he)
IL (1) IL212633A (he)
JO (1) JO3097B1 (he)
MX (1) MX2011005400A (he)
NZ (1) NZ592215A (he)
PA (1) PA8849001A1 (he)
PL (1) PL2358755T3 (he)
PT (1) PT2358755E (he)
SI (1) SI2358755T1 (he)
TR (1) TR201802841T4 (he)
TW (1) TWI477284B (he)
WO (1) WO2010059654A1 (he)
ZA (1) ZA201103586B (he)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
US9169329B2 (en) * 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
CA2816745C (en) 2010-11-03 2019-03-12 arGEN-X BV Anti c-met antibodies
CN102276726B (zh) * 2011-03-16 2014-02-19 常州新泉生物医药科技有限公司 肝细胞生长因子受体活性基团的融合蛋白
US20140301989A1 (en) * 2011-06-17 2014-10-09 Brian Johnstone Methods for increasing the potency and efficacy of stem cells
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
WO2013043452A1 (en) * 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
AR088920A1 (es) 2011-11-21 2014-07-16 Genentech Inc Purificacion de anticuerpos anti-c-met
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US9260531B2 (en) * 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
EP2992019B1 (en) * 2013-04-30 2019-03-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
JP2016527900A (ja) * 2013-08-14 2016-09-15 キアゲン マンスフィールド インコーポレイテッド ｃＭＥＴ核酸のマルチモード解析のための組成物および方法
EA035745B1 (ru) * 2013-10-14 2020-08-05 Янссен Байотек, Инк. Связующие молекулы на основе домена фибронектина типа iii с внедренными остатками цистеина
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10450376B2 (en) * 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN107613974B (zh) * 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
US11235063B2 (en) 2015-11-03 2022-02-01 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
US10927177B2 (en) 2016-02-05 2021-02-23 Helixmith Co., Ltd Methods of treatment using anti-c-met antibodies
GB2551372A (en) * 2016-06-16 2017-12-20 Bombardier Primove Gmbh A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
EA201990067A1 (ru) 2016-06-21 2019-07-31 Янссен Байотек, Инк. Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
WO2018021188A1 (ja) * 2016-07-26 2018-02-01 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
US10439449B2 (en) 2016-08-10 2019-10-08 Microsoft Technology Licensing, Llc Coupling device modules for inductive data transmission
RU2744914C2 (ru) * 2016-09-29 2021-03-17 Мицубиси Танабе Фарма Корпорейшн МОНОКЛОНАЛЬНЫЕ АГЕНТЫ, СВЯЗЫВАЮЩИЕ сМЕТ, ИХ КОНЪЮГАТЫ С ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ И ИХ ПРИМЕНЕНИЯ
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
HUE054500T2 (hu) * 2016-11-23 2021-09-28 Lilly Co Eli MET antitest hatóanyag konjugátumok
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
RU2759952C2 (ru) 2016-12-14 2021-11-19 Янссен Байотек, Инк. Cd8a-связывающие домены типа iii фибронектина
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
EP3630844A4 (en) 2017-05-30 2021-03-03 Chong Kun Dang Pharmaceutical Corp. NEW ANTI-C-MET ANTIBODY AND ITS USE
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
KR20230136758A (ko) * 2021-02-03 2023-09-26 마이틱 테라퓨틱스, 인크. 항체 및 이의 용도
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4320152A1 (en) 2021-04-08 2024-02-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
MX2023012128A (es) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Dominios tipo iii de la fibronectina que se unen a cd71.
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用
WO2024240634A1 (en) 2023-05-19 2024-11-28 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69220940T2 (de) 1991-05-10 1998-01-15 Pharmacia & Upjohn S.P.A., Mailand/Milano Verkürzte Formen den Hepatozyten Wachstumsfaktor (HGF) Rezeptors
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
CN101073668A (zh) 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
ATE465181T1 (de) * 2004-08-05 2010-05-15 Genentech Inc Humanisierte anti-cmet-antagonisten
ES2539790T3 (es) 2005-03-25 2015-07-06 Genentech, Inc. Métodos y composiciones para modular c-met hiperestabilizado
SG169382A1 (en) 2006-02-06 2011-03-30 Metheresis Translational Res S A Ch Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
WO2007101021A2 (en) * 2006-02-22 2007-09-07 Eli Lilly And Company Humanized anti-ghrelin antibodies
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2677799A1 (en) * 2007-02-08 2008-08-14 The Regents Of The University Of California Gnaq mutations in melanoma
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met

Also Published As

Publication number Publication date
CN102216333A (zh) 2011-10-12
JO3097B1 (ar) 2017-03-15
EA020398B1 (ru) 2014-10-30
DK2358755T3 (en) 2015-11-16
KR20110074612A (ko) 2011-06-30
US20120263723A1 (en) 2012-10-18
PL2358755T3 (pl) 2016-01-29
KR101334450B1 (ko) 2013-12-02
HRP20151019T1 (hr) 2015-10-23
TR201802841T4 (tr) 2018-03-21
JP5688027B2 (ja) 2015-03-25
ES2549760T3 (es) 2015-11-02
PA8849001A1 (es) 2010-06-28
US8398974B2 (en) 2013-03-19
AU2009316742B2 (en) 2012-06-07
US8217148B2 (en) 2012-07-10
NZ592215A (en) 2012-09-28
TWI477284B (zh) 2015-03-21
CN102216333B (zh) 2014-05-21
CY1116886T1 (el) 2017-04-05
AR074360A1 (es) 2011-01-12
HUE026058T2 (en) 2016-05-30
EA201170716A1 (ru) 2011-12-30
BRPI0922800A2 (pt) 2015-12-22
PT2358755E (pt) 2015-11-12
JP2012509881A (ja) 2012-04-26
SI2358755T1 (sl) 2015-10-30
IL212633A0 (en) 2011-07-31
CA2743508C (en) 2016-07-19
MX2011005400A (es) 2011-06-20
CA2743508A1 (en) 2010-05-27
ES2663825T3 (es) 2018-04-17
US20100129369A1 (en) 2010-05-27
WO2010059654A1 (en) 2010-05-27
AU2009316742A1 (en) 2010-05-27
EP2358755B1 (en) 2015-09-02
TW201023885A (en) 2010-07-01
EP2963058A1 (en) 2016-01-06
ZA201103586B (en) 2013-10-30
IL212633A (he) 2015-03-31
EP2358755A1 (en) 2011-08-24
EP2963058B1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
HK1158229A1 (en) C-met antibodies c-met
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
GB0821100D0 (en) Antibodies
GB0708002D0 (en) Antibodies
ZA201100300B (en) Anti-cd5 antibodies
IL209142A0 (en) Anti-flt3 antibodies
SI2146745T1 (sl) Penta-specifično protitelo
SI2200700T1 (sl) Nova protitelesa
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en) Antibodies
IL207581A0 (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
IL205073A0 (en) Anti-bst2 antibody
IL208281A0 (en) Substituted cyclohexyldiamines
ZA201007976B (en) Anti-pirb antibodies
IL209175A0 (en) Substituted qunazolines
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
EP2264071A4 (en) ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0817621D0 (en) Antibody
GB0817622D0 (en) Antibody

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191120